Engineered nanoparticles against MDR in cancer: The state of the art and its prospective

Current Pharmaceutical Design

Volumn 22, Issue 28, 2016, Pages 4360-4373

  Ahmad, Javed ^a   Akhter, Sohail ^b,c   Khan, Mohammad Ahmed ^d   Wahajuddin, Muhammad ^e   Greig, Nigel H ^f   Kamal, Mohammad Amjad ^g,h   Midoux, Patrick ^c   Pichon, Chantal ^c  

^a National Institute of Pharmaceutical Education and Research (NIPER)   (India)

^b Le Studium   (France)

^c CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^d HAMDARD UNIVERSITY   (India)

^e CENTRAL DRUG RESEARCH INSTITUTE   (India)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^h Enzymoics   (Australia)

Author keywords

Active targeting; Combinational drug targeting; Efflux transporter; HIFU; MDR; Multidrug resistance; Nanoparticles; Passive targeting; PH sensitive

Indexed keywords

NANOCARRIER; NANOPARTICLE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; MULTIDRUG RESISTANCE; NANOENGINEERING; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; BIOMEDICAL ENGINEERING; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; NEOPLASM;

BIOMEDICAL ENGINEERING; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84989234572     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160617112111     Document Type: Review

References (193)

1. Akhter S, Ahmad I, Ahmad MZ, et al. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets 2013; 13 (4): 362-78.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
3. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010; 596: 467-88.
4. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 2012; 12 (7): 494-501.
5. Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31 (8): 1397-407.
6. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 2012; 15 (1-2): 21-38.
7. Baguley B. Multidrug resistance in cancer. In: Zhou J, Ed. USA: Humana Press 2010; pp. 1-14.
8. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011; 14 (3): 150-63.
9. Gillet JP, Gottesman M. Mechanisms of multidrug resistance in cancer. In: Zhou J, Ed. Multi-drug Resistance in Cancer. USA: Humana Press 2001; pp. 47-76.
10. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30 (12): 679-92.
11. Yin Q, Shen J, Zhang Z, Yu H, Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev 2013; 30 (13-14): 1699-715.
12. Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release 2012; 162 (1): 45-55.
13. Dong XW, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010; 5 (4): 597-615.
14. Bu HH, Gao Y, Li YP. Overcoming multidrug resistance (MDR) in cancer by nanotechnology. Sci China Chem 2010; 53 (11): 2226-32.
15. Hu, CM, Zhang L. Nanoparticle based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83 (8): 1104-11.
16. Montesinos RN, Beduneau A, Pellequer Y, Lamprechta A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release 2012; 161 (1): 50-61.
17. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev 2012; 32 (6): 1220-62.
18. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 2009; 10 (8): 836-41.
19. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008; 26 (1): 74-85.
20. Ahmad J, Mir SR, Kohli K, Chuttani K, Mishra AK, Panda AK, Amin S. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging. Biomed Res Int 2014; 2014: 984756.
21. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82.
22. Dawar S, Singh N, Kanwar RK. Multifunctional and multi targeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discov Today 2013; 18 (23-24): 1292-300.
23. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013; 65 (13-14): 1748-62.
24. Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev 2013; 65 (13-14): 1731-47.
25. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013; 65 (13-14): 1866-79.
26. Ahmad J, Mir SR, Kohli K, Amin S. Quality by design approach for self nanoemulsifying system of paclitaxel. Sci Adv Mater 2014; 6 (8): 1778-91.
27. Schneider E, Hunke S. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol Rev 1998; 22 (1): 1-20.
28. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002; 62 (17): 5035-40.
29. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54 (2): 357-61.
30. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000; 60 (20): 5761-766.
31. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
32. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26 (4): 239-57.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1) 57-70.
34. Moll UM, Wolff S, Speidel D, Deppert W. Transcriptionindependent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005; 17 (6): 631-6.
35. Indran IR, Tufo G, Pervaiz S, Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 2011; 1807 (6): 735-45.
36. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005; 94: 143-96.
37. Schuyer M, van der Burg ME, Henzen-Logmans SC, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001; 85 (9): 1359-67.
38. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296 (5573): 1655-7.
39. Metzinger DS, Taylor DD, Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett 2006; 236 (2): 302-8.
40. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65 (20): 3145-67.
41. Li W, Melton DW. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012; 31 (19): 2412-22.
42. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006; 4 (2): 61-70.
43. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99 (19): 1441-54.
44. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992; 52 (22): 6371-4.
45. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004; 4 (10): 806-13.
46. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26 (2): 225-39.
47. Weber CE, Kuo PC. The tumor microenvironment. Surg Oncol 2012; 21 (3): 172-7.
48. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8 (9): 705-13.
49. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008; 132 (3): 164-70.
50. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4 (6): 437-47.
51. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11 (6): 393-410.
52. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58 (6): 776-84.
53. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34 (7): 592-602.
54. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011; 8 (6): 2032-8.
55. Wenzel M, Mahotka C, Krieg A, et al. Novel survivin-related members of the inhibitor of apoptosis (IAP) family. Cell Death Differ 2000; 7 (7): 682-3.
56. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9 (1): 28-39.
57. Longo-Sorbello GS, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 2001; 86 (2): 121-7.
58. Akhter S, Amin S, Ahmad J, et al. Nanotechnology to combat multidrug resistance in cancer. Resistance to Targeted ABC Transporters in Cancer. Switzerland: Springer International Publishing 2015; pp. 245-72.
59. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91 (3): 1071-121.
60. Perche F, Torchilin VP. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv 2013; 2013: 1-32.
61. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, longcirculating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009; 15 (6): 1973-80.
62. Torchilin VP. Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Ther Deliv 2010; 1 (2): 257-72.
63. Yang T, Choi MK, Cui FD, et al. Antitumor effect of paclitaxelloaded pegylated immunoliposomes against human breast cancer cells. Pharm Res 2007; 24 (12): 2402-11.
64. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65 (1): 36-48.
65. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60 (5): 1197-201.
66. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin. Cancer Res 2009; 15 (11): 3770-80.
67. Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011; 8 (3): 683-700.
68. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006; 114 (2): 153-62.
69. Zhang X, Guo S, Fan R, et al. Dual-functional liposome for tumor targeting and overcoming multi drug resistance in hepatocellular carcinoma cells. Biomaterials 2012; 33 (29): 7103-14.
70. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in Pglycoprotein-mediated drug resistant tumor cells. Int J Pharm 2007; 329 (1-2): 94-102.
71. Kataoka K, Matsumoto T, Yokoyama M, et al. Doxorubicin-loaded poly (ethylene glycol)-poly (beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000; 64 (1-3): 143-53.
72. Kwon, G., Naito, M., Yokoyama, M., Okano, T., Sakurai, Y., Kataoka, K. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J Control Release 1997; 48 (2-3): 195-201.
73. Yang X, Deng W, Fu L, et al. Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrugresistance modulator FG020326. J Biomed Mater Res A 2008; 86 (1): 48-60.
74. Lee AL, Dhillon SH, Wang Y, Pervaiz S, Fan W, Yang YY. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosisinducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Mol Biosyst 2011; 7 (5): 1512-22.
75. Akhter S. Jain G. K. Ahmad F. J. Khar R. K, Jain N, Khan Z. I, Talegaonkar S. Investigation of nanoemulsion system for transdermal delivery of domperidone: ex-vivo and in vivo studies. Curr Nanosci 2008; 4 (4): 381-90.
76. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009; 6 (3): 928-939.
77. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83 (8): 1104-11.
78. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 2012; 7 (10): 1577-90.
79. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006; 112 (3): 312-9.
80. Yang Y, Wang Z, Li M, Lu S. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 2009; 29 (2): 239-42.
81. Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009; 9: 399.
82. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011; 8 (3): 852-66.
83. Lei T, Srinivasan S, Tang Y, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 2011; 7 (3): 324-32.
84. Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011; 152 (3): 418-25.
85. Maeng JH, Lee DH, Jung KH, et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010; 31 (18): 4995-5006.
86. Lim J, Simanek EE. Triazine dendrimers as drug delivery systems: from synthesis to therapy. Adv Drug Deliv Rev 2012; 64 (9): 826-35.
87. Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 2013; 84 (1): 1-20.
88. Lee CC, Gillies ER, Fox ME, et al. A single dose of doxorubicinfunctionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 2006; 103 (45): 16649-54.
89. Qiu LY, Wang RJ, Zheng C, Jin Y, Jin LQ. Beta-cyclodextrincentered star-shaped amphiphilic polymers for doxorubicin delivery. Nanomedicine (Lond) 2010; 5 (2): 193-208.
90. Batrakova EV, Kelly DL, Li S, et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 2006; 3 (2): 113-23.
91. Chen YH, Tsai CY, Huang PY, et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 2007; 4 (5): 713-22.
92. Podsiadlo P, Sinani VA, Bahng JH, Kam NW, Lee J, Kotov NA. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 2008; 24 (2): 568-74.
93. Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ. Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv 2012; 9 (10): 1225-43.
94. Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal goldrhTNFnanomedicine. Clin Cancer Res 2010; 16 (24): 6139-49.
95. Gu YJ, Cheng J, Man CW, Wong WT, Cheng SH. Golddoxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 2012; 8 (2): 204-11.
96. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011; 5 (5): 3679-92.
97. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phy 2003; 36: 167-81.
98. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res 2011; 28 (2): 237-59.
99. Wang X, Zhang R, Wu C, et al. The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res A 2007; 80 (4): 852-60.
100. Huang IP, Sun SP, Cheng SH, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011; 10 (5): 761-9.
101. Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010; (8) 4: 4539-50.
102. Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale 2011; 3 (10): 4314-22.
103. Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009; 5 (23): 2673-7.
104. Sinha N, Yeow JT. Carbon nanotubes for biomedical applications. IEEE Trans Nanobiosci 2005; 4 (2): 180-95.
105. Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A, Prato M. Targeting carbon nanotubes against cancer. Chem Commun 2012; 48: 3911-26.
106. Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010; 4 (3): 1399-408.
107. Ahmad J, Amin S, Rahman M, et al. Solid matrix based lipidic nanoparticles in oral cancer chemotherapy: applications and pharmacokinetics. Curr Drug Metab 2015; 16 (8): 633-44.
108. Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010; 6 (2): 210-3.
109. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 2009; 37 (3-4): 508-13.
110. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2006; 119 (2): 255-69.
111. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6 (9): 688-701.
112. Sirova M, Mrkvan T, Etrych T, et al. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model. Pharm Res 2010; 27 (1): 200-8.
113. Yu Y, Wang ZH, Zhang L, et al. Mitochondrial targeting topotecanloaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials 2012; 33 (6): 1808-20.
114. Zhou J, Zhao WY, Ma X, et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 2013; 34 (14): 3626-38.
115. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targetedco-delivery of MDR-1siRNA and doxorubicin. ACS Nano 2011; 5 (6): 5202-13.
116. Zhang W, Shi Y, Chen Y, Ye J, Sha X, Fang X. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011; 32 (11): 2894-906.
117. Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010; 31 (8): 2371-9.
118. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005; 103 (2): 405-18.
119. Liu Y, Sun J, Lian H, Cao W, Wang Y, He Z. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxelloaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 2014; 103 (5): 1538-47.
120. Kabakov A, Makarova Y, Kudryavtsev V. Paclitaxel + 17AAG coencapsulated in nanoemulsion: overcoming drug resistance. XVIIth International Conference on Bioencapsulation. Groningen, Netherlands, September 24-26 2009.
121. Pramanik D, Campbell NR, Das S, et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012; 3 (6): 640-50.
122. Gou P, Liu W, Mao W, Tang J, Shen Y, Sui M. Self-assembling doxorubicin prodrug forming nanoparticles for cancer chemotherapy: synthesis and anticancer study in vitro and in vivo. J Mater Chem B 2013; 1 (3): 284-92.
123. Xu L, Li H, Wang Y, Dong F, Wang H, Zhang S. Enhanced activity of doxorubicin in drugresistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-basednanovectors. Oncol Lett 2014; 7 (2): 387-92.
124. Wang Y, Dou L, He H, Zhang Y, Shen Q. Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance. Mol Pharm 2014; 11 (3): 885-94.
125. He H, Chen S, Zhou J, et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013; 34 (21): 5344-58.
126. Cheng Y, Samia AC, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 2008; 130 (32): 10643-7.
127. Huang K, Ma H, Liu J. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012; 6 (5): 4483-93.
128. Chen J, Shi M, Liu P, et al. Reducible polyamidoamine-magnetic iron oxide self-assembled nanoparticles for doxorubicin delivery. Biomaterials 2014; 35 (4): 1240-8.
129. Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013; 7 (2): 994-1005.
130. Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010; 4 (3): 1399-408.
131. Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multi drug resistant human mammary tumor xenografts. Cancer Lett 2013; 334 (2): 263-73.
132. Cohen K, Emmanuel R, Kisin-Finfer E, Shabat D, Peer D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 2014; 8 (3): 2183-95.
133. Xiong XB, Ma Z, Lai R, Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010; 31 (4): 757-68.
134. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 2009; 63 (4): 711-22.
135. Yamashiro DJ, Maxfield FR. Regulation of endocytic processes by pH. Trends Pharmacol Sci 1998; 9 (6): 190-3.
136. Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD. Extracellular pH distribution in human tumours. Int J Hyperthermia 1995; 11 (2): 211-6.
137. Chen R, Khormaee S, Eccleston ME, Slater NK. The role of hydrophobic amino acid grafts in the enhancement of membranedisruptive activity of pH-responsive pseudo-peptides. Biomaterials 2009; 30 (10): 1954-61.
138. He Q, Gao Y, Zhang L, et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011; 32 (30): 7711-20.
139. Kim D, Gao ZG, Lee ES, Bae YH. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm 2009; 6 (5): 1353-62.
140. Husseini GA, Myrup GD, Pitt WG, Christensen DA, Rapoport NY. Factors affecting acoustically triggered release of drugs from polymeric micelles. J Control Release 2000; 69 (1): 43-52.
141. Husseini GA, Pitt WG, Christensen DA, Dickinson DJ. Degradation kinetics of stabilized pluronic micelles under the action of ultrasound. J. Control. Release 2009; 138 (1): 45-8.
142. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007; 13 (9): 2722-7.
143. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60 (10): 1153-66.
144. Chen S, Ding JH, Bekeredjian R, et al. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci USA 2006; 103 (22): 8469-74.
145. Kheirolomoom A, Dayton PA, Lum AF, et al. Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release 2007; 118 (3): 275-84.
146. Marin A, Muniruzzaman M, Rapoport N. Acoustic activation of drug delivery from polymeric micelles: effect of pulsed ultrasound. J Control Release 2001; 71 (3): 239-49.
147. Husseini GA, Christensen DA, Rapoport NY, Pitt WG. Ultrasonic release of doxorubicin from Pluronic P105 micelles stabilizedwith an interpenetrating network of N, N-diethylacrylamide. J Control Release 2002; 83 (2): 303-5.
148. Marin A, Sun H, Husseini GA, Pitt WG, Christensen DA, Rapoport NY. Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake. J Control Release 2002; 84 (1-2): 39-47.
149. Rapoport N, Marin A, Luo Y, Prestwich GD, Muniruzzaman MD. Intracellular uptake and trafficking of Pluronic micelles in drugsensitive and MDR cells: effect on the intracellular drug localization. J Pharm Sci 2002; 91 (1): 157-70.
150. Gao Z, Fain HD, Rapoport N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol Pharm 2004; 1 (4): 317-30.
151. Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 2005; 102 (1): 203-22.
152. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83 (8): 1104-1111.
153. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30 (7): 679-92.
154. Abeylath SC, Ganta S, Iyer AK, Amiji M. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc Chem Res 2011; 44 (10): 1009-17.
155. Chiu GN, Wong MY, Ling LU, et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr Drug Metab 2009; 10 (8): 861-74.
156. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011; 14 (3): 150-63.
157. Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007; 121 (8): 1830-8.
158. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007; 67 (10): 4843-50.
159. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012; 18 (2): 124-131.
160. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013; 49 (6): 1297-304.
161. Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007; 1768 (3): 678-87.
162. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007; 12 (1-2): 34-42.
163. Tran MA, Gowda R, Sharma A, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008; 68 (18): 7638-49.
164. Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 2009; 22 (4): 388-99.
165. Hussain M, Beale G, Hughes M, Akhtar S. Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-coglycolide) microsphere formulations for potential combination therapy in cancer. Int J Pharm 2002; 234 (1-2): 129-38.
166. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010; 10 (9): 3223-30.
167. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 2010; 74 (3): 467-73.
168. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 2012; 422 (1-2): 229-37.
169. Kumar P, Gulbake A, Jain SK. Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 2012; 29 (5): 355-419.
170. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83 (8): 1104-11.
171. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 2012; 17 (17-18): 1044-52.
172. Tardi PG, Dos Santos N, Harasym TO, et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009; 8 (8): 2266-75.
173. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006; 116 (3): 275-84.
174. Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 2001; 7 (1): 202-9.
175. Li X, Lu WL, Liang GW, et al. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Eur J Clin Invest 2006; 36 (6): 409-18.
176. Liang GW, Lu WL, Wu JW, et al. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 2008; 22 (4): 429-37.
177. Agrawal V, Paul MK, Mukhopadhyay AK. 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization. J Liposome Res 2005; 15 (3-4): 141-55.
178. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 2012; 160 (2): 281-9.
179. Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long circulating liposomes. Int J Pharm 2011; 416 (1): 296-9.
180. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxy nucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003; 21 (23): 3319-29.
181. Kim JY, Shim G, Choi HW, et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 2012; 33 (17): 4424-30.
182. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA 2009; 106 (19): 7957-61.
183. Kang SH, Cho HJ, Shim G, et al. Cationic liposomal codelivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm Res 2011; 28 (12): 3069-78.
184. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008; 70 (3): 718-25.
185. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464 (7291): 1067-70.
186. Maas ML, Specht JP, Buckwalter KC, Gittler J, Bechen K. Nursing home staffing and training recommendations for promoting older adults’ quality of care and life: Part 1. Deficits in the quality of care due to understaffing and undertraining. Res Gerontol Nurs 2008; 1 (2): 123-33.
187. Ren Y, Kang CS, Yuan XB, et al. Co-delivery of asmiR-21 and 5-FU by poly (amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2010; 21 (3): 303-14.
188. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK. Surface engineered dendrimers for dual drug delivery: a receptor upregulation and enhanced cancer targeting strategy. J Drug Target 2008; 16 (10): 758-72.
189. Lee IH, An S, Yu MK, Kwon HK, Im SH, Jon S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release 2011; 155 (3): 435-41.
190. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010; 31 (13): 3694-706.
191. Song XR, Zheng Y, He G, et al. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J Pharm Sci 2010; 99 (12): 4874-9.
192. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. AngewChem Int Ed Engl 2009; 48 (30): 5418-29.
193. Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl 2015, 8: 55-66.